GlaxoSmithKline, Theravance Reveal Positive Results over their New Lung Treatment Formula

GlaxoSmithKlineIf British drug giant GlaxoSmithKline Plc (GSK, GSK. L) and US biopharma firm Theravance Inc. (THRX) are to be believed then we can soon expect an effective lung disease treatment to serve all those suffering from the common and dangerous cancer.

In its statements of Monday, the pharmaceuticals companies revealed about their four pivotal phase III studies that were being run over the investigational combination drug and its effects.

They confirmed that the experiments have shown positive results and a significant improvement has been noticed in the conditions of patients suffering from chronic obstructive pulmonary disease, or COPD.

According to reports, GlaxoSmithKline is developing a new formula with the combination of two investigational bronchodilator molecules i. e. LAMA/LABA and Theravance. Successful completion of the studies is being expected to give the commercial market a new treatment for the illness from the end of this year.

The two 24-week long studies that were performed by GlaxoSmithKline Plc and Theravance, Inc. over 4,000 patients with COPD to compare and understand the combination LAMA/LABA, its components and placebo are over and their results are out.

Both the studies have shown positive results and the companies are hoping to fill in the markets with an effective treatment of lung cancer soon by the end of this year.